School of Medicine
Showing 611-620 of 661 Results
-
Rob W.
3D Biomedical Engineer, Radiology - Diagnostic Radiology
Current Role at StanfordDesigning custom surgical models and patient-specific implants for SHC and LPCH!
-
Nolan Williams
Associate Professor of Psychiatry and Behavioral Sciences (Major Laboratories & Clinical Translational Neurosciences Incubator) and, by courtesy, of Radiology (Neuroimaging and Neurointervention)
BioNolan Williams, M.D. is an Associate Professor of Psychiatry and Behavioral Sciences at Stanford University and Director of the Stanford Brain Stimulation Lab. The long-term goals of his research program are to develop innovative technologies and therapeutics capable of modulating the neural circuitry disrupted in mood disorders, OCD, and other neuropsychiatric conditions. His team has been developing neuroimaging-based approaches to precisely target therapeutic delivery and predict treatment responses to therapeutic neuromodulation and psychedelics. Dr. Williams earned his M.D. and completed his dual residencies in neurology and psychiatry at the Medical University of South Carolina (MUSC). Triple board-certified in general neurology, general psychiatry, as well as behavioral neurology and neuropsychiatry, Dr. Williams brings a comprehensive background in clinical neuroscience to his role as a clinically active neuropsychiatrist. His expertise extends to the development and implementation of novel therapeutics, including devices and novel compounds, for central nervous system illnesses.
Over the past decade, Dr. Williams’ laboratory alongside collaborators at Stanford University have pioneered multiple novel therapeutic and human neuroscience approaches. Notably, Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) is the world's first non-invasive, rapid-acting neuromodulation approach for treatment-resistant depression. SAINT received FDA Breakthrough Device Designation Status (2021) and FDA Clearance (2022) and is the first psychiatric treatment to be covered by Medicare New Technology Add-On Payment (NTAP). As of April 2024, SAINT has been reimbursed for patients suffering from severe depression within inpatient psychiatric units. The SAINT technology is being deployed both clinically and in research protocols in laboratories and hospitals worldwide. Dr. Williams also has an expertise in psychedelic medicines for neuropsychiatric illness and is the first investigator to conduct mechanistic clinical trials exploring the neurobiological effects of ibogaine.
His research accomplishments have garnered international recognition, earning prestigious awards from the Pritzker Neuropsychiatric Disorders Consortium, One Mind Institute, Wellcome Leap Foundation, International Brain Stimulation Conference, National Institute of Mental Health (Biobehavioral Research Award for Innovative New Scientists), Society of Biological Psychiatry (A. E. Bennett Award), along with multiple awards from the Brain Behavior Research Foundation (most notably the Gerald L. Klerman Award and Colvin Prize). His work has been featured in Scientific American, The New York Times, The Washington Post, USA Today, CBS Sunday Morning, and the TODAY Show. -
Wesley Williams
Postdoctoral Scholar, Radiology
Current Research and Scholarly InterestsFirstly, a goal of mine is to fashion a novel scatter-based parameter for PET reconstruction algorithms to improve image resolution via determining a more detailed scatter/true ratio estimate via binning the photons that have scattered once, twice, and perhaps, many more times.
Secondly, AI drug discovery application towards radiotracers may quicken experimentation by determining the formulations worth trying. Moreover, it may be able to characterize efficacy (biodistribution) (self-update). -
Roger Wise
Director, Additive Manufacturing and Prototyping Facility, Rad/Precision Health and Integrated Diagnostics
Current Role at StanfordDr. Wise is the Director of the Additive Manufacturing and Prototyping Facility (AMPF), a shared-user 3D printing center supporting Stanford University's research enterprise. AMPF currently consists of state-of-the-art, manufacturing-quality, commercial 3D printers (Carbon S2, M2, & L1, and Carbon Smart Part Washer). This advanced 3D printing facility brings digital design, prototyping, and small-scale production to the Stanford ecosystem. It serves as an integrated innovation hub, forming a key pillar of research and commercialization for investigators spanning the Stanford campus, Canary Center, and Silicon Valley. More information can be found at https://ampf.stanford.edu/.
